• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

    2.420 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 805
    Open 2.420
    Bid (Size) 2.400 (100)
    Ask (Size) 2.410 (200)
    Prev. Close 2.420
    Today's Range 2.420 - 2.420
    52wk Range 0.4603 - 7.130
    Shares Outstanding 61,540,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    News headline image
    ProKidney Corp (NASDAQ:PROK) Reports Q3 2025 Earnings and Clinical Progress ↗
    ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy. 
    Via Chartmill

    Performance

    YTD
    +8.5%
    +8.5%
    1 Month
    +3.0%
    +3.0%
    3 Month
    -25.8%
    -25.8%
    6 Month
    -44.2%
    -44.2%
    1 Year
    +32.2%
    +32.2%

    More News

    Read More
    News headline image
    Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
    Via MarketMinute
    News headline image
    ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
    From ProKidney
    Via GlobeNewswire
    News headline image
    ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
    From ProKidney
    Via GlobeNewswire
    News headline image
    ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    News headline image
    ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
    From ProKidney
    Via GlobeNewswire
    News headline image
    SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC ↗
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
    From ProKidney
    Via GlobeNewswire
    News headline image
    Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% ↗
    Via Benzinga
    News headline image
    ProKidney Reports 78 Percent Gain in Q2 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss ↗
    Via Chartmill
    News headline image
    ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
    From ProKidney
    Via GlobeNewswire
    News headline image
    Meet the Biotech Stock That Rocketed 775% Higher ↗
    Via The Motley Fool
    News headline image
    This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Unusual volume stocks are being observed in Tuesday's session. ↗
    Via Chartmill
    News headline image
    Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
    From ProKidney
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill

    Frequently Asked Questions

    Is ProKidney Corp. - Class A Ordinary Shares publicly traded?
    Yes, ProKidney Corp. - Class A Ordinary Shares is publicly traded.
    What exchange does ProKidney Corp. - Class A Ordinary Shares trade on?
    ProKidney Corp. - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for ProKidney Corp. - Class A Ordinary Shares?
    The ticker symbol for ProKidney Corp. - Class A Ordinary Shares is PROK on the Nasdaq Stock Market
    What is the current price of ProKidney Corp. - Class A Ordinary Shares?
    The current price of ProKidney Corp. - Class A Ordinary Shares is 2.420
    When was ProKidney Corp. - Class A Ordinary Shares last traded?
    The last trade of ProKidney Corp. - Class A Ordinary Shares was at 01/07/26 04:00 PM ET
    What is the market capitalization of ProKidney Corp. - Class A Ordinary Shares?
    The market capitalization of ProKidney Corp. - Class A Ordinary Shares is 148.93M
    How many shares of ProKidney Corp. - Class A Ordinary Shares are outstanding?
    ProKidney Corp. - Class A Ordinary Shares has 149M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.